Angioplasty, Transluminal, Percutaneous Coronary

Cardiovascular

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.

$69.4B marketMature→ Stable30 products15 companies

Key Trends

FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure

Career Verdict

Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#	Product	Company	Revenue	Share	Stage	Trend	LOE
1	ELIQUIS (Apixaban)	Bristol Myers Squibb	$18.3B	26%	Peak	Stable	15.0yr
2	JARDIANCE (Empagliflozin)	Boehringer Ingelheim	$8.8B	13%	Peak	Growing	8.6yr
3	XARELTO (Rivaroxaban)	Johnson & Johnson	$6.3B	9%	Peak	Stable
4	FARXIGA (Dapagliflozin)	AstraZeneca	$4.3B	6%	Peak	Growing	15.4yr
5	JANUVIA (Sitagliptin)	Merck & Co.	$4.1B	6%	LOE_Approaching	Declining	1.1yr

#1ELIQUIS

$18.3B

Bristol Myers Squibb·Peak15.0yr

#2JARDIANCE

$8.8B

Boehringer Ingelheim·Peak8.6yr

#3XARELTO

$6.3B

Johnson & Johnson·Peak

#4FARXIGA

$4.3B

AstraZeneca·Peak15.4yr

#5JANUVIA

$4.1B

Merck & Co.·LOE_Approaching1.1yr

Drug Class Breakdown

FXa Inhibitors (Apixaban/Rivaroxaban)

$42.8B(62%)

Mature, stable revenue base

SGLT2 Inhibitors

$13.1B(19%)

Growing in heart failure and renal indications

DPP4 Inhibitors

$4.1B(6%)

Declining as LOE approaches 2027

ARBs and Combination Therapies

$3.4B(5%)

Stable in heart failure management

Endothelin Receptor Antagonists and Prostacyclin Agonists

$1.8B(3%)

Niche pulmonary hypertension market

Career Outlook

Stable

Cardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.

Breaking In

Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.

For Experienced Professionals

Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.

In-Demand Skills

Healthcare economics and payer management (anticoagulation safety monitoring, cost-effectiveness)Real-world evidence generation (postmarket surveillance for FXa inhibitors)Digital health and remote patient monitoring integrationClinical trial execution in large, established patient populationsRegulatory expertise in label expansions (SGLT2 inhibitor indications)

Best For

Commercial/Sales roles (mature market execution)Medical Science Liaisons (managing healthcare provider relationships on established therapies)Clinical Operations/Project Managers (managing large Phase 3/4 programs)Regulatory Affairs (label expansion strategy, patent cliff preparation)Health Economics and Outcomes Research (demonstrating value in competitive anticoagulation market)

Hiring Landscape

$130K-$210K

Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.

1,386

Open Roles

Companies Hiring

Departments

Top Hiring Companies

337

317

261

By Department

Commercial(34%)

$210K

Clinical Operations(21%)

$180K

Engineering(13%)

$145K

Medical Affairs(1%)

$201K

Research & Development(1%)

$194K

Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

CordisFL - Miami Lakes

3 programs

7F Ensure Medical Vascular Closure DevicePHASE_11 trial

Vascular access site closurePHASE_21 trial

Manual CompressionPHASE_31 trial

Active Trials

NCT00574691Completed93Est. Oct 2007

NCT00533156Completed30Est. Aug 2007

NCT00345631Completed488Est. Sep 2007

BiotronikGermany - Berlin

1 program

Orsiro™ Drug Eluting Stent groupN/A1 trial

Active Trials

NCT02039739Completed1,007Est. Jan 2022

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

CordisManual Compression

CordisVascular access site closure

Cordis7F Ensure Medical Vascular Closure Device

BiotronikOrsiro™ Drug Eluting Stent group

Clinical Trials (4)

Total enrollment: 1,618 patients across 4 trials

NCT00345631 CordisManual Compression

Safety and Effectiveness Study of the Ensure Medical Vascular Closure Device

Start: Feb 2007Est. completion: Sep 2007488 patients

Phase 3Completed

NCT00533156 CordisVascular access site closure

Plug Arterial Closure System (PACS, 7F)

Start: Jul 2007Est. completion: Aug 200730 patients

Phase 2Completed

NCT00574691 Cordis7F Ensure Medical Vascular Closure Device

ECLIPSE Feasibility Trial (Ensure's Vascular Closure Device Speeds Hemostasis Trial) EU

Start: Jun 2007Est. completion: Oct 200793 patients

Phase 1Completed

NCT02039739 BiotronikOrsiro™ Drug Eluting Stent group

Orsiro™ Drug Eluting Stent in Routine Clinical Practice

Start: Jun 2014Est. completion: Jan 20221,007 patients

N/ACompleted

Related Jobs in Cardiovascular

Director, Clinical Trial Liaison - Northern Midwest: Illinois; Indiana; Michigan; Minnesota; Missouri; Iowa; North Dakota

Executive Director, Data, AI & Collaboration Services

Kardigan

Princeton, New Jersey, United States, South San Francisco, California, United States

3d ago

$269K - $340K/yr

Territory Manager- PV - Los Angeles Proper

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Hypertension(936)Heart Failure(877)Coronary Artery Disease(769)Atrial Fibrillation(615)Pulmonary Arterial Hypertension(207)Acute Coronary Syndrome(140)Atherosclerosis(123)Aortic Valve Stenosis(121)Pulmonary Hypertension(111)Congestive Heart Failure(94)

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.